Isomab Ltd Revenue and Competitors
Employee Data
- Isomab Ltd has 13 Employees.
- Isomab Ltd grew their employee count by 18% last year.
Isomab Ltd's People
| Name | Title | Email/Phone |
|---|
Isomab Ltd Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.5M | 29 | -12% | N/A | N/A |
#2 | $15.7M | 86 | 4% | N/A | N/A |
#3 | $87.9M | 405 | 25% | $292M | N/A |
#4 | $2.6M | 680 | 30% | $631.7M | N/A |
#5 | $14.9M | 96 | -8% | $81M | N/A |
#6 | $44.8M | 231 | 0% | $132.9M | N/A |
#7 | $7.6M | 49 | -37% | N/A | N/A |
#8 | $17.4M | 112 | 12% | N/A | N/A |
#9 | $334.6M | 1349 | 11% | £994.6M | N/A |
#10 | $830.2M | 5095 | 12% | N/A | N/A |
What Is Isomab Ltd?
IsomAb is taking a different approach to identify, evaluate and develop isoform specific antibodies to treat disease where patients currently have limited or no treatment options.\nIsomAb is developing isoform specific antibodies and it has identified, using a combined bioinformatics/knowledge-based platform approach, ISM-001 which specifically inhibits the VEGF-A165b isoform of Vascular Endothelial Growth Factor-A (VEGF-A); based on 20 years of research by our two Founders, the evidence shows reducing serum levels of VEGF-A165b is key to ensuring new blood vessel formation in patients with ischemic disease.
keywords:N/A
N/A
Total Funding
13
Number of Employees
N/A
Revenue (est)
18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Nottingham
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.9M | 13 | -13% | N/A |
#2 | $2.2M | 14 | 8% | N/A |
#3 | N/A | 15 | 0% | N/A |
#4 | $3M | 15 | -17% | N/A |
#5 | $2.9M | 16 | N/A | N/A |